Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered Paper session - SARS-CoV-2 and cancer

1559O - Efficacy and toxicity of BNT162b2 vaccine in cancer patients

Date

21 Sep 2021

Session

Proffered Paper session - SARS-CoV-2 and cancer

Presenters

Ithai Waldhorn

Citation

Annals of Oncology (2021) 32 (suppl_5): S1129-S1163. 10.1016/annonc/annonc713

Authors

I. Waldhorn1, I. Ben-Aharon1, R. Holland2, A. Peer2, M. Halberthal3, T.G. Goshen - Lago2

Author affiliations

  • 1 Division Of Oncology, Rambam Medical Center, 3525408 - Haifa/IL
  • 2 Division Of Oncology, Rambam Medical Center, 3109601 - Haifa/IL
  • 3 General Management, Rambam Medical Center, 3525408 - Haifa/IL
More

Resources

Login to access the resources on OncologyPRO.

Abstract 1559O

Background

Efficacy and safety profile of COVID-19 vaccines had been acquired from phase III studies. Nevertheless, cancer patients were not represented in these trials. In 1/2021 mass vaccination of high-risk population, including cancer patients, was initiated in Israel. We aimed to prospectively evaluate efficacy, immunogenicity and safety of BNT162b2 vaccine in cancer patients.

Methods

Cancer patients on active treatment were prospectively enrolled following first dose of BNT162b2 or after a second dose. Serum was collected after each dose and additionally in case of seronegativity. An age-matched cohort of healthcare workers served as controls. Questionnaires regarding sociodemographics and adverse reactions were employed at serum collection. FDA-approved assay was used to assess IgG at all time-points. Patients’ electronic medical records were reviewed for documentation of COVID-19 infection, blood counts, liver enzymes and imaging studies.

Results

The study included 232 cancer patients and 261 controls. Following first dose 29% of patients were seropositive compared with 84% of controls (p<0.001). Following second dose seropositive rate reached 86%. Rate per 1000-person days after first dose were 12.5 for patients and 48.5 for controls. Chemotherapy reduced immunogenicity (OR 0.41 (95%CI 0.17-0.98). In seronegative patients, rate of documented leukopenia reached 39%. No COVID19 cases were documented throughout the study period except two cases following the first dose. Reported adverse events resembled former published studies.

Conclusions

Our results indicate the BNT162b2 appear to be safe and effective in cancer patients. There is a pronounced lag in antibody production compared with non-cancer controls, however seroconversion occurred in most patients after the second dose. Future real-world data is warranted to determine the long-term efficacy of the vaccine with regard to type of anti-cancer treatment.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

ICRF.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings